UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of January
2018
Commission File Number 000-50112
RepliCel Life Sciences Inc.
(Translation of registrant’s name
into English)
Suite 900 - 570 Granville Street,
Vancouver, British Columbia V6C 3P1
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) ☐
Note: Regulation S-T Rule
101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security
holders.
SUBMITTED HEREWITH
99.1 News
Release dated January 25, 2018 - RepliCel CEO Provides 2018 Shareholder Update
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
RepliCel Life Sciences Inc.
/s/ Lee Buckler
Lee Buckler, President
Date: January 25, 2018
3
Exhibit 99.1
RepliCel CEO Provides 2018 Shareholder Update
With a new Asian partnership and 2017
deliverables met, RepliCel is primed and ready for expansion
VANCOUVER, Jan. 25, 2018 /CNW/ - RepliCel Life Sciences
Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation
technologies in aesthetics and orthopedics, is pleased to provide an update to shareholders from its President and CEO, Mr. R.
Lee Buckler.
Dear Shareholders,
I am very pleased to be providing this 2018 update. The Company
had a very successful 2017, which has only paved the way for a successful year as we enter into 2018. We are ramping up for expansion
of all our programs and are actively focused on additional partnership discussions to drive the Company towards maturation. These
are exciting times and we look forward to sharing more news as RepliCel continues to gain momentum taking its place as a biotech
industry leader.
Looking back over the past 24 months, 2016 was about restructuring
and refinancing the Company, 2017 was about delivering promised clinical and injector milestones, and now 2018 is about expansion.
With the rebuilding that the Company has accomplished in the
past 24 months, RepliCel has now set the stage to execute across multiple fronts over the next 24 months. Armed with clinical data,
functioning device prototypes, a new partner committed to financing our programs in Greater China, and significant capital to execute
our programs elsewhere through 2019, we have now positioned RepliCel to deliver on its next phase across several platforms at a
faster pace.
We have ongoing research programs at the University of British
Columbia in Vancouver, the Shiseido-funded clinical research in Japan, and our dermal injector development taking place in Europe.
Expanding from there, we are laying plans for development programs with lead experts in North America and Europe, phase 2 clinical
trials in Europe, new clinical trials in Hong Kong and mainland China, regulatory clarity with the United States FDA, and exploring
other deals currently under discussion.
In 2018, shareholders should expect to see:
| · | The launch of a European multi-centre, phase 2 clinical
trial measuring the impact of RCS-01 injections on aging skin. |
| · | Completion of commercial-grade prototypes for the
RCI-02 dermal injector. |
| · | Filing of a CE-mark application for our dermal injector
seeking the regulatory marketing approval needed to commercially launch the device in Europe and Hong Kong. |
| · | Preparations for launching the device in Hong Kong
by licensing partner, YOFOTO (China) Health Industry Co. Ltd. |
| · | Data from the clinical research being funded by Shiseido
in Japan measuring the benefit of RCH-01 injections in men and women suffering from hair loss due to androgenic alopecia. |
| · | Data from the research program at UBC identifying
different genetic marker expression profiles of various cell populations in the hair follicle with an aim of potentially improving
cell selection, manufacturing, and clinical outcomes. |
| · | The launch of tendon repair (RCT-01) and skin rejuvenation
(RCS-01) clinical trial activity in Hong Kong and/or Mainland China funded by YOFOTO. |
| · | The launch of planned product development projects
with various partners intended to add significant value to our programs. |
| · | A meeting with the FDA reviewing one or more of our
programs. |
| · | Business development activity which may well lead
to the execution of other commercial partnerships. |
Unlike previous years, not only are we are financed to move
through these milestones, we have new, significant non-dilutive funding commitments for much of this expansion, subject to successful
closing of the deal with YOFOTO.
The pending investment from and partnership with YOFOTO, announced
earlier this month, brings to RepliCel a new major shareholder committed not only to finance the programs licensed for Greater
China but also to the overall success of the Company. The dilutive investment upfront will be used to fund our programs outside
of Asia. This will be counterbalanced with YOFOTO's funding of our programs in Greater China which will bring significant value
to the Company as they generate clinical data and commercialize products. RepliCel shareholders can also look forward to the Company
receiving further non-dilutive milestone and royalty payments as part of the YOFOTO partnership.
With the YOFOTO partnership including the dermal injector,
we now have a commercial partner able to launch the device commercially in Hong Kong once we have obtained CE-mark approval. This
means we now have commercial partnerships in place not only with the potential for near-term commercial launch of RCH-01 in Japan
but also a near-term launch of the injector of the device in Hong Kong.
As I outlined in our September press release, we have leveraged
our progress in 2017 into a very exciting pipeline of ongoing partnership discussions. While we have now announced the YOFOTO partnership
focused on product development and commercialization in Greater China, we have other deals we are in a position to consider in
the months ahead. These potential partnerships offer unique opportunities to position and capitalize the Company on its path to
increasing maturity.
About RepliCel Life Sciences
RepliCel is a regenerative medicine company focused on developing cell therapies for aesthetic and orthopedic conditions affecting
what the Company believes is approximately one in three people in industrialized nations, including aging/sun-damaged skin, pattern
baldness, and chronic tendon degeneration. These conditions, often associated with aging, are caused by a deficit of
healthy cells required for normal tissue healing and function. The Company's product pipeline is comprised of RCT-01 for tendon
repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is currently being co-developed with, and under exclusive
license by, Shiseido for certain Asian countries. All product candidates are based on RepliCel's innovative technology, utilizing
cell populations isolated from a patient's healthy hair follicles. RepliCel has also developed a proprietary injection device,
RCI-02, optimized for the administration of its products and licensable for use with other dermatology applications. Please visit www.replicel.com for
additional information.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy
of this release.
Disclaimer for Forward-Looking Statements
This press release contains forward-looking statements
and information that involve various risks and uncertainties regarding future events, including, but not limited to, statements
regarding: the completion of the transaction with YOFOTO for financing the Company's programs in Greater China, and providing significant
capital to execute the Company's programs elsewhere through 2019; the Company conducting development programs with lead experts
in North America and Europe, phase 2 clinical trials in Europe and new clinical trials in Hong Kong and mainland China; the Company
obtaining regulatory clarity with the United States FDA; the launch of a European multi-centre, phase 2 clinical trial measuring
the impact of RCS-01 injections on aging skin; completion of commercial-grade prototypes for the RCI-02 dermal injector; the filing
of a CE-mark application for our dermal injector seeking the regulatory marketing approval needed to commercially launch the device
in Europe and Hong Kong; obtaining clinical data from the clinical research being funded by Shiseido in Japan and data from the
research program at UBC identifying different genetic marker expression profiles of various cell populations in the hair follicle;
the launch of tendon repair (RCT-01) and skin rejuvenation (RCS-01) clinical trial activity in Hong Kong and/or Mainland China
funded by YOFOTO; the launch of planned product development projects with various partners; the execution of other commercial partnerships;
that YOFOTO will fund the Company's programs in Greater China resulting in the generation of clinical data and commercialized products;
the Company receiving further non-dilutive milestone and royalty payments as part of the YOFOTO transaction; that YOFOTO will become
a commercial partner for the injector device; and the near-term commercial launch of RCH-01 in Japan.
These statements are only predictions and involve
known and unknown risks which may cause actual results and the Company's plans and objectives to differ materially from those expressed
in the forward-looking statements, including: risks related to the Company and YOFOTO being able to negotiate and enter into the
definitive agreements required for the transaction with YOFOTO, risks related to the Company obtaining the approval of the TSX-V
and its shareholders for the transaction with YOFOTO, risks related to YOFOTO obtaining consent for the transaction from the required
parties and applicable regulatory authorities; risks that the Company's products may not perform as, or have the benefits, expected;
risks that the Company's products may not be accepted and adopted by the public; the risk that the Company will not obtain CE mark
clearance for its injector device; the risk that there will be delays enrolling clinical trial participants or commencing any clinical
or research programs; the risk that the Company will receive negative results from the Company's clinical trials; the effects of
government regulation on the Company's business; risks associated with the Company obtaining all necessary regulatory approvals
for its various programs; risks associated with the Company's ability to obtain and protect rights to its intellectual property;
risks and uncertainties associated with the Company's ability to raise additional capital; and other factors beyond the Company's
control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot
guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date
on which such statement is made and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking
statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated
events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess
in advance the impact of such factors on the Company's business or the extent to which any factor, or combination of factors, may
cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of
the information set forth herein and should also refer to the risk factor disclosure outlined in the Company's annual report on
Form 20-F for the fiscal year ended December 31, 2016 and other periodic reports filed from time-to-time with the Securities and
Exchange Commission on Edgar at www.sec.gov and with the British Columbia Securities Commission on SEDAR at http://www.sedar.com/.
SOURCE RepliCel Life Sciences Inc.
View original content with multimedia: http://www.newswire.ca/en/releases/archive/January2018/25/c6454.html
%CIK: 0001205059
For further information: Lee Buckler, CEO and President, 604-248-8693,
info@replicel.com
CO: RepliCel Life Sciences Inc.
CNW 06:00e 25-JAN-18
This regulatory filing also includes additional resources:
ex991.pdf
RepliCel Life Sciences (CE) (USOTC:REPCF)
Historical Stock Chart
From Aug 2024 to Sep 2024
RepliCel Life Sciences (CE) (USOTC:REPCF)
Historical Stock Chart
From Sep 2023 to Sep 2024